Drug-induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases.


Journal

British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323

Informations de publication

Date de publication:
03 2019
Historique:
received: 11 09 2018
revised: 08 11 2018
accepted: 23 11 2018
pubmed: 5 12 2018
medline: 8 2 2020
entrez: 5 12 2018
Statut: ppublish

Résumé

Linear immunoglobin A (IgA) bullous dermatosis is a rare autoimmune dermatosis considered spontaneous or drug-induced (DILAD). We assessed all DILAD cases, determined the imputability score of drugs and highlighted suspected drugs. Data for patients with DILAD were collected retrospectively from the French Pharmacovigilance network (from 1985 to 2017) and from physicians involved in the Bullous Diseases French Study Group and the French Investigators for Skin Adverse Reactions to Drugs. Drug causality was systematically determined by the French imputability method. Of the 69 patients, 42% had mucous membrane involvement, 20% lesions mimicking toxic epidermal necrolysis (TEN), 21% eosinophil infiltrates and 10% keratinocytes necrosis. Direct immunofluorescence, in 80%, showed isolated linear IgA deposits. Vancomycin (VCM) was suspected in 39 cases (57%), 11 had TEN-like lesions, as compared with three without VCM suspected. Among the 33 patients with a single suspected drug, 85% had an intrinsic imputability score of I4. Among them, enoxaparin, minocycline and vibramycin were previously unpublished. For all patients, the suspect drug was withdrawn; 15 did not receive any treatment. First-line therapy for 31 patients was topical steroids. Among the 60 patients with available follow-up, 52 achieved remission, 10 without treatment. Four patients experienced relapse, four died and five had positive accidental rechallenges. There is no major clinical difference between DILAD and idiopathic linear IgA bullous dermatosis, but the former features a higher prevalence of patients mimicking TEN. VCM, suspected in more than half of the cases, might be responsible for more severe clinical presentations. We report three new putative drugs.

Identifiants

pubmed: 30511379
doi: 10.1111/bcp.13827
pmc: PMC6379232
doi:

Substances chimiques

Enoxaparin 0
Vancomycin 6Q205EH1VU
Minocycline FYY3R43WGO
Doxycycline N12000U13O

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

570-579

Informations de copyright

© 2018 The British Pharmacological Society.

Références

J Am Acad Dermatol. 2012 Jun;66(6):988-94
pubmed: 22169257
Ann Dermatol Venereol. 2011 Mar;138(3):214-20
pubmed: 21397151
J Clin Invest. 1990 Mar;85(3):812-20
pubmed: 2107211
Clin Dermatol. 1991 Jul-Sep;9(3):383-92
pubmed: 1806226
Therapie. 1985 Mar-Apr;40(2):111-8
pubmed: 4002188
Br J Dermatol. 2014 Dec;171(6):1602-4
pubmed: 24909099
Br J Clin Pharmacol. 2019 Mar;85(3):570-579
pubmed: 30511379
Dermatology. 2013;227(3):209-13
pubmed: 24135381
Ann Dermatol Venereol. 1993;120(11):847-8
pubmed: 8210142
J Invest Dermatol. 2019 Apr;139(4):835-841
pubmed: 30543900
J Am Acad Dermatol. 2018 Jun;78(6):1090-1096
pubmed: 29274348
J Dermatol. 2008 Nov;35(11):737-43
pubmed: 19120770
Australas J Dermatol. 2001 Aug;42(3):196-9
pubmed: 11488715
J Am Acad Dermatol. 1994 Feb;30(2 Pt 1):187-92
pubmed: 7904616
Br J Dermatol. 2010 Apr;162(4):743-50
pubmed: 19886889
Br J Dermatol. 2014 Nov;171(5):1248-53
pubmed: 24684224
Mayo Clin Proc. 2000 Sep;75(9):967-70
pubmed: 10994833
Br J Dermatol. 2013 Nov;169(5):1041-8
pubmed: 23815152
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508
J Eur Acad Dermatol Venereol. 2008 Sep;22(9):1131
pubmed: 18221336
Br J Dermatol. 2017 Jul;177(1):212-222
pubmed: 27995619
Acta Derm Venereol. 1981;61(5):439-41
pubmed: 6172936
J Am Acad Dermatol. 2000 Feb;42(2 Pt 2):316-23
pubmed: 10640923
Ann Dermatol Venereol. 2011;138(4):302-6
pubmed: 21497257
Clin Exp Dermatol. 2017 Apr;42(3):299-302
pubmed: 28084616
Br J Dermatol. 1997 Mar;136(3):406-11
pubmed: 9115927
J Invest Dermatol. 2018 Jul;138(7):1473-1480
pubmed: 29410066
J Am Acad Dermatol. 2010 May;62(5):897-8
pubmed: 20398825
Therapie. 2013 Mar-Apr;68(2):69-76
pubmed: 23773347
Arch Dermatol. 1976 Jun;112(6):837-8
pubmed: 782363
Int J Dermatol. 2009 Sep;48(9):1006-10
pubmed: 19702992
Br J Dermatol. 2013 Jul;169(1):210-1
pubmed: 23448154
Dermatology. 1999;199(1):25-30
pubmed: 10449953
Acta Derm Venereol. 2015 Apr;95(4):466-71
pubmed: 25350667

Auteurs

Bethsabée Garel (B)

Department of Dermatology, Assistance Publique-Hôpitaux de Paris (APHP), Henri-Mondor Hospital, 94010, Créteil, France.

Saskia Ingen-Housz-Oro (S)

Department of Dermatology, Assistance Publique-Hôpitaux de Paris (APHP), Henri-Mondor Hospital, 94010, Créteil, France.
EA 7379 EpiDermE, Université Paris Est Créteil Val de Marne UPEC, Créteil, France.
Reference Center for toxic bullous diseases and severe drug reactions, Créteil, France.

Daniele Afriat (D)

Regional Center of Pharmacovigilance, APHP, Pitié-Salpêtrière Hospital, Paris, France.

Catherine Prost-Squarcioni (C)

Dermatology Department, APHP, Avicenne Hospital, Bobigny, France.
Pathology Department, APHP, Avicenne Hospital, Bobigny, France.
Université Paris 13, Bobigny, France.

Florence Tétart (F)

Department of Dermatology, Rouen University Hospital, Rouen, France.

Benoit Bensaid (B)

Drug Allergy Unit-CCR2A, Department of Allergy and Clinical Immunology, CHU Lyon-Sud, Pierre Benite, France.

Corina Bara Passot (C)

Department of Dermatology, Le Mans Hospital, Le Mans, France.

Marie Beylot-Barry (M)

Department of Dermatology, Bordeaux University Hospital, Bordeaux, France.

Vincent Descamps (V)

Department of Dermatology, APHP, Bichat Claude Bernard Hospital, Paris Diderot University.

Sophie Duvert-Lehembre (S)

Department of Dermatology, University Hospital of Lille, Lille, France.

Sabine Grootenboer-Mignot (S)

Department of Immunology, APHP, Bichat Claude Bernard Hospital, Paris, France.

Géraldine Jeudy (G)

Department of Dermatology, Dijon University Hospital, Dijon, France.

Angèle Soria (A)

Department of Dermatology and Allergology, APHP, Tenon Hospital, Paris, France.
Sorbonne Université, Faculté de Médecine Sorbonne Université, Paris, France.
Inserm, UMR 1135, Paris, France.

Marie Blanche Valnet-Rabier (MB)

Regional Center of Pharmacovigilance, University Hospital Jean Minjoz, Besançon, France.

Annick Barbaud (A)

Reference Center for toxic bullous diseases and severe drug reactions, Créteil, France.
Department of Dermatology and Allergology, APHP, Tenon Hospital, Paris, France.
Sorbonne Université, Faculté de Médecine Sorbonne Université, Paris, France.

Frédéric Caux (F)

Dermatology Department, APHP, Avicenne Hospital, Bobigny, France.
Université Paris 13, Bobigny, France.

Bénédicte Lebrun-Vignes (B)

EA 7379 EpiDermE, Université Paris Est Créteil Val de Marne UPEC, Créteil, France.
Reference Center for toxic bullous diseases and severe drug reactions, Créteil, France.
Regional Center of Pharmacovigilance, APHP, Pitié-Salpêtrière Hospital, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH